Medicxi's antibody experiment

Medicxi Ventures' first investment since spinning out from Index Ventures is likely to be an outlier for the firm. Rather than pursuing its primary path of being the sole investor that plucks a single asset out of academia, the firm is part of a syndicate that is funding Capella BioScience Ltd., which has multiple internally generated antibodies.

Last week, Capella raised £11 million ($15.6 million) in a tranched series A round from Advent Life Sciences, Medicxi and Osage University Partners. ...